In this study data from people with metastatic castration-resistant prostate cancer (mCRPC) with bone metastasis are studied. mCRPC is a prostate cancer which has spread to other parts of the body even when the amount of testosterone in the body was reduced. Bone metastasis is when the cancer has spread to the bones. The study drug, radium-223, is currently available as a treatment for mCRPC with bone metastasis. But, its combination with certain other cancer treatments may lead to medical problems. Therefore the instructions about how doctors should use radium-223 with other cancer treatments were changed. In this study, the researchers want to learn more about how doctors are now using radium-223 to treat patients with mCRPC and bone metastasis. The participants in this study will include men in Denmark, Germany, or the Netherlands. They will not have received radium-223 before. They will have at least 6 months of medical records before starting treatment with radium-223. The researchers will collect the participants' medical records up to December 2020. The researchers will review information from the participants' medical records and medical claims from hospitals where the participants received radium-223. They will look at the medical records of participants who first started receiving radium-223 before there were new instructions about using it with other cancer treatments. They will also look at the medical records of participants who first started receiving radium-223 after there were new instructions. They will then count how many participants received other specific cancer treatments with radium-223. They will compare the results of the participants' who received radium-223 before the new instructions and those who received it after the new instructions. There are no required visits or tests in this study.
Study Type
OBSERVATIONAL
Enrollment
1,067
Prescribed by physicians.
Many Locations
Multiple Locations, Denmark
Many Locations
Multiple Locations, Germany
Many Locations
Multiple Locations, Netherlands
The proportion of patients who use radium-223 in combination with abiraterone acetate
Time frame: Data will be collected from Nov 2013 to Dec 2020
The proportion of patients who use radium-223 in combination with other systemic therapies for mCRPC, except luteinising hormone-releasing hormone (LHRH) analogues
Time frame: Data will be collected from Nov 2013 to Dec 2020
The proportion of patients who use radium-223 without having received at least two prior lines of systemic therapy for mCRPC, except LHRH analogues
Time frame: Data will be collected from Nov 2013 to Dec 2020
The difference between before and after the label change periods in the proportion of patients who use radium-223 in combination with abiraterone acetate
Time frame: Data will be collected from Nov 2013 to Dec 2020
The difference between before and after the label change periods in the proportion of patients who use radium-223 in combination with other systemic therapies for mCRPC, except luteinising hormone-releasing hormone (LHRH) analogues
Time frame: Data will be collected from Nov 2013 to Dec 2020
The difference between before and after the label change periods in the proportion of patients who use radium-223 without having received at least two prior lines of systemic therapy for mCRPC, except LHRH analogues
Time frame: Data will be collected from Nov 2013 to Dec 2020
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.